Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 7/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15820966 | 0.92 | SLC5A2 (0.51) | SLC5A2PYGLACHETYR | |
| SCHEMBL15820964 | 0.92 | SLC5A2 (0.51) | SLC5A2PYGLACHETYR | |
| SCHEMBL27730414 | 0.80 | TYR (0.55) | SLC5A2TYR | |
| SCHEMBL14294567 | 0.79 | LGALS3 (0.52) | — | |
| SCHEMBL15743866 | 0.79 | LGALS3 (0.52) | — | |
| SCHEMBL8224471 | 0.79 | SLC5A2 (0.55) | SLC5A2 | |
| SCHEMBL15981949 | 0.79 | ACHE (0.43) | SLC5A2ACHETYR | |
| SCHEMBL12844835 | 0.79 | SLC5A2 (0.55) | SLC5A2 | |
| SCHEMBL29197612 | 0.79 | SLC29A1 (0.40) | SLC5A2ACHETYR | |
| SCHEMBL29197613 | 0.79 | SLC29A1 (0.40) | SLC5A2ACHETYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913761-B2 | 2,7-dibromospiro[fluorene-9,4′-piperidine] compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200270293-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2020-08-27 | — | — | US | disclosed |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190106450-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS INCORPORATED | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106450-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | SLC5A2 89/4885PYGL 1524/4885ACHE 2337/4885 |
| US-10913761-B2 | 2,7-dibromospiro[fluorene-9,4′-piperidine] compounds | DHPS, CFTR, FDPS | SLC5A2 2191/4885PYGL 4491/4885ACHE 2257/4885 |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | MPI, MANBA, MAN2A1 | SLC5A2 89/4885PYGL 1524/4885ACHE 2337/4885 |
| US-20200270293-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | SLC5A2 89/4885PYGL 1524/4885ACHE 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.